HomeGrowth Hormone & Muscle › FST-344

Follistatin isoform (344 amino acids) / myostatin and activin antagonist

FST-344

Research use only

Written by pep4U Editorial Team · Last reviewed July 8, 2026

Follistatin-344 is a form of the natural protein follistatin that blocks myostatin and activin to allow greater muscle growth.

Class / typeFollistatin isoform (344 amino acids) / myostatin and activin antagonist
CategoryGrowth Hormone & Muscle
Status (Jul 2026)Research use only

How it works

It is a binding protein that binds myostatin and activin A with high affinity in the extracellular space, preventing them from activating ActRIIB and thereby releasing the natural limit on muscle growth.

Known / used for

Studied mainly via AAV-mediated gene therapy in Becker muscular dystrophy and inclusion body myositis, and in preclinical animal models for muscle hypertrophy and anti-fibrotic effects.

Positives

Gene-therapy trials reported increased muscle volume and strength over two years without serious adverse events; preclinical models show dramatic muscle growth.

Negatives & risks

Human data are very limited, injectable protein protocols are unvalidated, and follistatin's roles in reproductive and other TGF-beta pathways raise off-target and long-term safety concerns.

Frequently asked questions

What is FST-344?
Follistatin-344 is a form of the natural protein follistatin that blocks myostatin and activin to allow greater muscle growth. It is a binding protein that binds myostatin and activin A with high affinity in the extracellular space, preventing them from activating ActRIIB and thereby releasing the natural limit on muscle growth.
What is FST-344 used or researched for?
Studied mainly via AAV-mediated gene therapy in Becker muscular dystrophy and inclusion body myositis, and in preclinical animal models for muscle hypertrophy and anti-fibrotic effects.
Is FST-344 FDA-approved or legal?
NOT FDA-approved. It remains investigational (gene-therapy and preclinical research only) with no approved human product, and myostatin-inhibiting agents are prohibited by WADA under class S4.5.
What are the main risks or downsides of FST-344?
Human data are very limited, injectable protein protocols are unvalidated, and follistatin's roles in reproductive and other TGF-beta pathways raise off-target and long-term safety concerns.

Legal / regulatory status

Recommended supplies

See all supplies →

As an Amazon Associate we earn from qualifying purchases.

← Back to Growth Hormone & Muscle